Location: United States
Total raised: $157.8M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2026 | Series B | $115M | Janus Hend... |
| 07.09.2022 | Series D | $42.8M | - |
Mentions in press and media 11
| Date | Title | Description |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 17.02.2026 | ILiAD Biotechnologies Secures $115M to Accelerate Advanced Pertussis Vaccine Development | ILiAD Biotechnologies, a clinical-stage biotech firm, raised $115 million in Series B funding. RA Capital Management led the investment. Janus Henderson and BNP Paribas Asset Management Alts also participated. The capital will advance BPZE1... |
| 11.02.2026 | ILiAD Biotechnologies Raises $115M in Series B Funding | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotech company, raised $115M in Series B funding. The round was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Man... |
| 10.02.2026 | ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Seri... |
| 10.02.2026 | ILiAD Biotechnologies snags $115M series B for whooping cough vaccine | ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation whooping cough vaccine candidate. Led by RA Capital Management, and with participation from new partners Janus Hende... |
| 03.12.2025 | ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model | ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The... |
| 07.09.2022 | ILiAD Biotechnologies of Weston closes $42.8M Series D | Facebook Tweet Pin LinkedIn Email ILiAD Biotechnologies, a clinical stage biotech company based in Weston, raised $42.8M in Series D funding. The round was led by New York-based Knott Partners. Under CEO and founder Dr. Keith Rubin, ILiAD B... |
| 06.09.2022 | ILiAD Biotechnologies Scores $42.8M | WESTON, FL, ILiAD Biotechnologies today announced the closing of a $42.8 million Class D round of financing. >> Click here for more funding data on ILiAD Biotechnologies >> To export ILiAD Biotechnologies funding data to PDF... |
| 06.09.2022 | ILiAD Biotechnologies Closes $42.8M Series D Financing | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotechnologies company, raised $42.8M in Series D funding. The round was led by Knott Partners. The company intends to use the funds to conduct a Phase 2b Human Challenge study to de... |
| 19.12.2018 | ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center | WESTON, Fla.–(BUSINESS WIRE)–December 19, 2018– ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the initial closing of a Class C fi... |
Show more